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Reidelberger R, Haver A, Chelikani PK, Apenteng B,
Perriotte-Olson C, Anders K, Steenson S, Blevins JE. Effects of
leptin replacement alone and with exendin-4 on food intake and
weight regain in weight-reduced diet-induced obese rats. Am J Physiol
Endocrinol Metab 302: E1576–E1585, 2012. First published April
17, 2012; doi:10.1152/ajpendo.00058.2012.—Weight loss in obese
humans produces a relative leptin deficiency, which is postulated
to activate potent orexigenic and energy conservation mechanisms
to restrict weight loss and promote weight regain. Here we deter-
mined whether leptin replacement alone or with GLP-1 receptor
agonist exendin-4 attenuates weight regain or promotes greater
weight loss in weight-reduced diet-induced obese (DIO) rats. Forty
percent restriction in daily intake of a high-fat diet in DIO rats for
4 wk reduced body weight by 12%, body fat by 29%, and plasma
leptin by 67% and normalized leptin sensitivity. When food re-
striction ended, body weight, body fat, and plasma leptin increased
rapidly. Daily administration of leptin [3-h intraperitoneal (ip)
infusions (4 nmol·kg1·h1)] at onset and end of dark period for 3
wk did not attenuate hyperphagia and weight regain, nor did it
affect mean daily meal sizes or meal numbers. Exendin-4 (50
pmol·kg1·h1) infusions during the same intervals prevented
postrestriction hyperphagia and weight regain by normalizing meal
size. Coadministration of leptin and exendin-4 did not reduce body
weight more than exendin-4 alone. Instead, leptin began to atten-
uate the inhibitory effects of exendin-4 on food intake, meal size,
and weight regain by the end of the second week of administration.
Plasma leptin in rats receiving leptin was sevenfold greater than in
rats receiving vehicle and 17-fold greater than in rats receiving
exendin-4. Together, these results do not support the hypothesis
that leptin replacement alone or with exendin-4 attenuates weight
regain or promotes greater weight loss in weight-reduced DIO rats.
food restriction; hyperphagia; leptin sensitivity; glucagon-like pep-
tide-1 receptor agonist
OBESITY IS A CHRONIC, stigmatized, and costly disease that is
rarely curable and is increasing in prevalence in most of the
world (4). Current therapies for producing weight loss in obese
individuals, i.e., dieting, exercise, and medications, are woe-
fully ineffective in producing long-term weight loss. This is
likely due to redundancy and plasticity in the complex physi-
ological system that controls food intake and regulates energy
reserves. Many experts believe that multidrug therapy aimed at
different components of this regulatory system will be required
to produce a significant reduction in adiposity (4, 13, 21, 22).
An important early step in the development of antiobesity
drugs is determining whether chronic administration of anorex-
igenic substances, alone or in combination, can produce a
prolonged decrease in daily food intake and adiposity in
experimental animals. Methods of administration usually in-
clude daily injections or insertion of an osmotic minipump
beneath the skin or into the peritoneal cavity to deliver sub-
stances continuously for 1 wk or more. Treatments typically
produce only transient decreases in food intake, resulting in
relatively small or no decreases in body weight and adiposity
(e.g., see Refs. 16, 28, 38, 43, and 44). Likely reasons include
development of a compensatory increase in food intake be-
tween injections, desensitization and downregulation of recep-
tors in response to continuous or frequent administration of
high doses, and weight loss-induced activation of counteract-
ing orexigenic and energy conservation mechanisms to restore
energy reserves (14, 24, 37, 39).
We have developed a novel experimental model that permits
precise control of intravenous (iv) or intraperitoneal (ip) ad-
ministration of anorexigenic substances to rats tethered via
infusion swivels to computer-controlled pumps (7–10, 30–32,
34). Rats are free to move, eat, and drink within their home
cages, and their indwelling catheters remain functional for
many months. Measurement of food bowl weight, recorded by
computer every 20 s, permits daily assessment of the instan-
taneous effects of dose and pattern of administration of sub-
stances on food intake and meal patterns. Adjustments in
dosing regimen can be performed daily within rats in an
attempt to define a strategy that minimizes compensatory
hyperphagia between doses, receptor desensitization and down-
regulation, and activation of counteracting orexigenic mecha-
nisms.
We used this experimental model to help resolve an inter-
national controversy among many scientists from academia
and industry on whether the gut hormone peptide YY (3–36)
[PYY(3–36)] reduces food intake and body weight (2, 7, 9, 15,
27, 43). We demonstrated that 3-h iv infusion of PYY(3–36),
which is more likely to simulate postprandial secretion of the
gut hormone, dose-dependently reduces short-term food intake
in rats and that daily intermittent PYY(3–36) infusions reduce
body weight in lean and diet-induced obese (DIO) rats (7, 9,
11). We concluded that, because of its short half-life, bolus
systemic injection of PYY(3–36) to rodents, the method used
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routinely by most investigators to study mechanisms of action
of putative satiety hormones, does not reliably reduce food
intake and body weight. We also concluded that continuous
subcutaneous(SQ) infusion of PYY(3–36), unlike intermittent
systemic infusion, was ineffective in reducing body weight in
the prior studies because it probably produced desensitization
and downregulation of receptors for PYY(3–36). Others have
argued that bolus ip injections can produce acute stress and that
stress can mask the inhibitory effect of anorexigenic substances
on food intake (1). This is not a factor with our experimental
model.
Recently, we have used our experimental model to deter-
mine the effects of a wide range of dosing regimens of
PYY(3–36), amylin, amylin receptor agonist salmon calci-
tonin, naltrexone, and glucagon-like peptide-1 (GLP-1) recep-
tor agonist exendin-4 on daily food intake, body weight, and
adiposity in DIO rats (10, 11, 29, 31–33). Of these substances,
only a single dosing regimen of a single substance (exendin-4)
was able to produce a sustained 15–30% reduction in daily
food intake and weight loss for 2 wk (31). However, exen-
din-4’s effect waned after 17 days, and coadministration of
PYY(3–36) and exendin-4 at various dosing combinations did
not produce a more prolonged effect than the GLP-1 receptor
agonist exendin-4 alone despite recent studies suggesting that
chronic elevation in gut hormones PYY(3–36) and GLP-1 may
cause the significant weight loss that occurs with Roux-en-Y
gastric bypass surgery (19, 20).
In each of our studies, the gradual decline in efficacy of the
various treatments to reduce food intake and body weight in the
DIO rats did not appear to be due to desensitization or down-
regulation of receptors (10, 11, 29, 31–33). This is because
food intake increased significantly when treatments were dis-
continued for 1 day following apparent losses in treatment
efficacies. If desensitization or downregulation of receptors
was primarily responsible for loss in a treatment efficacy, then
discontinuing the treatment should have had little, if any, effect
on food intake. Rather, our results suggest that activation of
potent orexigenic mechanisms occurred gradually to counteract
the inhibitory effect of the anorexigenic substances on food
intake and energy reserves. The nature of these mechanisms
remains to be determined. One possibility is that early treat-
ment-induced reductions in daily food intake and energy re-
serves elicit a delayed compensatory response to restore energy
balance, which is mediated by a reduction in leptin signaling to
the brain (24, 37). In support of this hypothesis, Rosenbaum et
al. (37) have shown that a 10% weight reduction in obese
humans reduces energy expenditure, satiation, and perception
of amount of food eaten and that low-dose leptin replacement
reverses these effects (36, 37).
Here, we determined whether leptin replacement alone or
with GLP-1 receptor agonist exendin-4 attenuates weight re-
gain or promotes greater weight loss in weight-reduced, DIO
rats provided free access to a high-fat diet. We first determined
the effects of food restriction-induced weight loss in DIO rats
on food intake, body weight, body fat content, and plasma
leptin. We next identified a leptin-dosing regimen that would
produce a sustained reduction in food intake and body weight
in a lean rat model. We then determined the effects of inter-
mittent ip infusion of this dosing regimen of leptin alone and in
combination with exendin-4 on hyperphagia and weight regain
in weight-reduced DIO rats. We then assessed whether the
inability of this leptin treatment to prevent weight regain or
promote greater weight loss in the weight-reduced DIO rats
was due to a relative leptin insensitivity in these rats.
METHODS
Exendin-4 and Leptin
Exendin-4 was synthesized and purified as described previously
(31). Recombinant mouse leptin was obtained from Dr. A. F. Parlow,
National Hormones and Peptides Program, Harbor-UCLA Medical
Center, Los Angeles, CA. Leptin was dissolved at 50 nmol/ml in
phosphate-buffered saline (PBS) at pH 8. One-milliliter aliquots were
then stored at 70°C until they were used.
Animals
The Animal Studies Subcommittee of the Omaha Veterans Affairs
Medical Center approved the protocol. Outbred male lean (Sprague-
Dawley; Charles River Laboratories) and DIO rats (CD IGS; Charles
River Laboratories) were used in the experiments. There appears to be
no consensus in defining obesity in rats, although percent body fat
20% body weight is likely (25). Here, we induced obesity (25%
body fat), as described previously (31), with a 45% fat diet (D12451;
Research Diets, New Brunswick, NJ) over a 4- to 6-mo period. Total
body fat mass was determined noninvasively using quantitative magnetic
resonance (EchoMRI 700; Echo Medical Systems, Houston, TX).
Effects of Food Restriction-Induced Weight Loss in DIO Rats on
Food Intake, Body Weight, Body Fat, and Plasma Leptin
This experiment assessed whether food restriction-induced weight
loss in DIO rats produces a post-restriction-induced hyperphagia and
weight regain that could possibly be caused by a relative leptin
deficiency. Sixty DIO rats were divided into three groups of 20 rats
each with matched body weights (858  21, 853  13, and 852  19
g) and fat masses (271  16, 262  11, and 262  13 g). One group
was provided free access to the 45% fat diet for 7 wk. In the other two
groups of rats, a 40% reduction in the daily intake of the high-fat diet
was imposed for 2 or 4 wk, followed by 3 wk of free access to the
high-fat diet. Restricted rats were fed 60% of the amount of food
consumed by the ad libitum fed group on the previous day. In 10 rats
of each group, weights of food bowls were recorded by computer to
determine hourly cumulative intake for each rat; in the remaining rats,
food bowls were weighed at the start and end of each day. Body
weights were measured weekly. Body fat contents were determined,
and blood samples were taken in groups of rats at the end of intervals
of food restriction and refeeding (Fig. 1). Rats were anesthetized by
isoflurane inhalation, and blood samples were taken by cardiac punc-
ture for measurement of plasma leptin concentration (Leptin ELISA,
EZML-82K; Millipore, Billerica, MA).
Fig. 1. Timeline of experiment examining the effects of 40% daily food
restriction (FR) for 2 or 4 wk, followed by 3 wk of ad libitum (ad lib) feeding,
on body weight, body fat, plasma leptin concentration, and daily food intake in
diet-induced obese (DIO) rats. Arrows denote time and no. of rats euthanized
for blood sampling and measurement of body fat.
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Effects of Daily ip Infusions of Leptin and Exendin-4 Alone and
Together on Post-Food Restriction-Induced Hyperphagia, Weight
Regain, and Plasma Leptin in DIO Rats
If the hyperphagia and weight regain that follow prolonged food
restriction and weight loss in DIO rats are due in part to a reduction
in leptin signaling to the brain, then administration of leptin alone or
with the anorexigenic peptide exendin-4 should attenuate postrestric-
tion weight regain or produce greater weight loss.
Results from a series of preliminary experiments examining the
effects of leptin administration in lean rats were used to define a leptin
dosing regimen for this experiment in DIO rats. We first determined
the dose response effects of a single, 3-h iv infusion of leptin (2, 4, 6,
and 12 nmol·kg1·h1) at dark onset on food intake during the dark
period in lean rats. We then determined the effects of two 3-h iv
infusions of leptin at the minimal effective dose of 4 nmol·kg1·h1
at the onset of the dark and light periods each day for 10 days on daily
food intake, body weight, and body fat in lean rats. We then compared
the effects of a 3-h iv vs. ip infusion of leptin (4 and 6 nmol·kg1·h1)
at dark onset on food intake in lean rats, since the next longer
experiment with DIO rats would administer leptin daily by ip rather
than iv infusion because of the relatively limited long-term patency of
iv catheters. We then determined the effects of twice daily 3-h ip infu-
sions of leptin (4 nmol·kg1·h1) and exendin-4 (50 pmol·kg1·h1) alone
and in combination for 3 wk on food intake, body weight, body fat,
and plasma leptin in weight-reduced DIO rats.
Dose response effects of iv infusion of leptin on food intake in lean
rats. Male rats (310–430 g) were housed individually in hanging wire
mesh cages in a room with controlled temperature (19–21°C) and a
12:12-h light-dark cycle. Rats were provided pelleted or powdered rat
chow (Labdiet, 5001 Rodent diet; PMI Nutrition International, Brent-
wood, MO) and water ad libitum. The procedure for implantation of
a jugular vein catheter for peptide infusions has been described
previously (45). Catheters were kept patent by flushing with 0.2 ml of
heparinized saline (20 U/ml) on alternate days and plugged with
stainless-steel wire. The animals were allowed1 wk to recover from
surgery. Rats were then adapted to being chronically tethered to an
infusion swivel (Instech Laboratories, Plymouth Meeting, PA) for 1
wk before the start of the experiments. The jugular vein catheter was
connected to a 40-cm length of tubing passed through a protective
spring coil connected between a lightweight saddle worn by the rat
and the swivel. Rats had ad libitum access to ground chow that was
provided fresh each day 3 h before dark onset. In a series of four
experiments, rats (n  16/experiment) received a single, 3-h jugular
vein infusion of leptin at 2, 4, 6, and 12 nmol·kg1·h1 in 0.15 M
NaCl and 0.1% BSA at 3 ml/h via a syringe infusion pump
(PHD2000, Harvard Apparatus, South Natick, MA) beginning 15 min
before dark onset; pumps were turned on and off by computer. In each
experiment, each of the 16 rats received vehicle and a single dose of
leptin in counterbalanced order at 72-h intervals. Food intake cumu-
lated hourly for 12 h after dark onset was determined from continuous
computer recording of changes in food bowl weight. At the end of an
experiment, data from a rat were excluded if its jugular vein catheter
was not patent. A catheter was deemed patent if the rat lost conscious-
ness within 10 s of a bolus injection of the short-acting anesthetic
Brevital (1 mg in 0.5 ml of saline) into the catheter.
Effects of daily iv infusions of leptin on food intake and body weight
in lean rats. Thirty-two male rats implanted with iv catheters and
tethered to infusion swivels were provided powdered rat chow from
1100 to 0900 the next morning (dark period: 2100–900). Setup and
routine maintenance were performed each day from 0900 to 1100.
During a 7-day baseline, all rats received two daily iv infusions of
vehicle (0.15 M NaCl, 0.1% BSA, 1 ml/h) from 1100 to 1400 and
2100 to 2400. Animals were then divided into two groups, one to
receive vehicle (n  16) and the other leptin (n  16), matched for
body weight (417  8 vs. 414  8 g) at end of baseline. During the
next 10 days, rats received two daily infusions of vehicle or leptin (4
nmol·kg1·h1) from 1100 to 1400 and 2100 to 2400. This leptin dose
was the minimal effective dose that inhibited food intake in the
previous experiment determining the dose response effects of iv
infusion of leptin on food intake in lean rats. Daily food intake was
determined from continuous computer recording of changes in food
bowl weight. Rats were weighed again at end of the 10-day period,
and body fat was measured. Data from a rat were excluded if its
jugular vein catheter was determined to not be patent.
Effects of iv vs. ip infusion of leptin on food intake in lean rats.
Methods were identical to those described in the preceding experi-
ment determining the dose-dependent effects of iv infusion of leptin
on food intake, except that each rat (n  16, 370–520 g) was
implanted with an ip as well as an iv catheter, as described previously
(31). In the first experiment, rats randomly received ip infusion of
vehicle, ip infusion of leptin at 4 nmol·kg1·h1, and iv infusion of
leptin at 4 nmol·kg1·h1 on days separated by 48 h. In a subse-
quent experiment, the same rats received vehicle and iv and ip
infusions of leptin at 6 nmol·kg1·h1.
Effects of daily ip infusions of leptin and exendin-4 alone and
together on post-food restriction-induced hyperphagia, weight regain,
and plasma leptin in DIO rats. Intraperitoneal catheters were im-
planted as described previously (31). One hundred twenty-six DIO
rats with ip catheters tethered to infusion swivels were divided into six
groups of 21 rats each with matched body weights (740  11, 730 
14, 722  16, 735  14, 724  20, and 734  18 g) and fat masses
(181  10, 194  12, 167  10, 187  10, 171  10, and 175  8
g). One group was provided free access to the 45% fat diet for 7 wk.
The other five groups were food restricted for 4 wk to 60% of the
amount of food consumed by the ad libitum-fed group on the previous
day. During the next 5 days, the food-restricted rats continued to be
restricted while receiving on each day two 3-h ip infusions of 0.9%
saline and 0.1% BSA from 1100 to 1400 and 2000 to 2300 (dark
period from 1100 to 2300). To define a daily exendin-4 dosing
strategy that reduces daily food intake in ad libitum-fed DIO rats by
40%, the ad libitum-fed rats received 60, 20, 15, 0, and 30 pmol/h
of exendin-4 during the same periods on the 5 consecutive days,
preceded by a loading dose that was one-third of the hourly dose. The
30 pmol/h dosing rate (50 pmol·kg1·h1) reduced daily food intake
by 38%.
During the next 3 wk, the group of rats that had been fed ad libitum
(group 1) continued to be fed ad libitum while receiving two daily
infusions of vehicle from 1100 to 1400 and 2000 to 2300. During this
same 3-wk period, four of the five groups of rats that had been food
restricted were fed ad libitum and were infused daily during the same
periods with vehicle (group 2), exendin-4 [group 3; 30 pmol/h (50
pmol·kg1·h1)], leptin [group 4; 2,200 pmol/h (4 nmol·kg1·h1)],
and exendin-4 plus leptin at these doses (group 5). Rats in the
remaining group that had been food restricted (group 6) were pair-fed
daily the mean amount of food ingested by the exendin-4-treated
group on the previous day. Daily food intake was determined from
continuous computer recording of changes in food bowl weight or by
measuring the weight of food bowls at the beginning and end of each
day. Meal parameters (meal size and no. of meals) were determined
using a minimum meal size criterion of 50 mg and a minimum
intermeal interval criterion of 15 min, as recommended by Zorrilla et
al. (49). Rats were weighed weekly. At the end of the 3-wk treatment
period, some rats from each group received their 3-h treatments at
dark onset without food present and were then anesthetized, and blood
samples were taken by cardiac puncture for measurement of plasma
leptin concentration.
DIO rats in this study were provided only a calorically dense
high-fat diet. Most obese people trying to lose weight also try to avoid
eating palatable calorically dense foods, but most people ultimately
fail to sustain this effort and regain lost weight. Pharmacotherapies
that can reduce the strong drive to eat palatable calorically dense
foods after weight loss are likely to be more successful in promoting
and sustaining weight loss. For several years now we have been using
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this DIO rat model in an attempt to identify a pharmacotherapy that
will reduce consumption of a palatable high-fat food.
Leptin Sensitivity in Age-Matched Lean, DIO, and Weight-Reduced
DIO Rats
Leptin sensitivity is reduced in obese subjects, and weight loss in
obese subjects increases leptin sensitivity (24). We assessed whether
the inability of leptin replacement to prevent weight regain in our
weight-reduced DIO rats was due to a relative leptin insensitivity in
these rats. Detection of an increase in leptin receptor signaling protein,
phosphorylated signal transducer and activator of transcription 3
(pSTAT3), in the arcuate nucleus (ARC) by immunostaining has
become the gold standard for assessing leptin sensitivity, because
ARC pSTAT3 increases rapidly with stimulation of leptin receptor
and because increases in ARC pSTAT3 are usually attributable to
leptin action (12, 24, 35). We measured leptin sensitivity in 1) age-
matched lean rats (619  9 g body wt, 11.9  0.3% body fat; n  6),
2) DIO rats (965 78 g body wt, 30 1% body fat; n 5), and 3) DIO
rats (initially 955  41 g body wt, 29  1% body fat; n  5) after a
weight loss of 10.3 0.7% to 856 33 g body wt was induced. Weight
loss in DIO rats was induced by restricting daily intake of their 45% fat
diet by 40% for 4 wk.
Rats from each group had food removed at light onset and received
an ip injection of leptin (125 nmol/kg) 4–6 h later. Thirty minutes
after injection, rats were anesthetized with isoflurane and then imme-
diately perfused transcardially with cold saline then 4% paraformal-
dehyde in PBS. Peak expression of ARC pSTAT3 occured 30 min
after leptin injection (17). Brains were placed in 4% paraformalde-
hyde-PBS for 24 h and then placed in 70% ethanol (EtOH) prior to
paraffin embedding. Coronal sections (6 m) sampled at 120-m
intervals through the ARC [bregma 3.48 to 2.76 mm; (26)] were
obtained using a rotary microtome, slide-mounted using a floatation
water bath (37°C), and baked for 30 min at 60°C to give 40 slides/
brain with two sections/slide. Sections were deparaffinized in Leica
Bond dewax solution (Leica Microsystems, Buffalo Grove, IL) and
rehydrated through 95% EtOH. Immunohistochemical staining of
pSTAT3 was performed using a modification of previously published
methods (23, 46), using a Leica Bond-MAX automated immunos-
tainer (Leica Microsystems). An antigen retrieval (heat-induced
epitope retrieval) technique was used in which slides were incubated
in citrate buffer (pH 6.0, Bond Epitope Retrieval Solution 1; Leica
Microsystems) at 100°C for 10 min. Endogenous peroxidase activity
was blocked for 5 min using 3% H2O2, followed by blocking in 10%
normal goat serum (Jackson ImmunoResearch Laboratories, West
Grove, PA) in Tris-buffered saline for 20 min at room temperature.
Slides were incubated with a primary rabbit anti-pSTAT3 antibody
(1:1,000; Sigma-Aldrich, St. Louis, MO) or normal rabbit IgG isotype
control (1:1,000; R & D Systems, Minneapolis, MN), both in Bond
Primary Antibody Diluent (Leica Microsystems), for 30 min at room
temperature. Sections were incubated with goat anti-rabbit poly-
horseradish peroxidase polymer secondary detection (Leica Microsys-
tems) for 8 min at room temperature. Sections were then incubated
with 3,3=-diaminobenzidine chromagen substrate (Bond Mixed Refine
3,3=-diaminobenzidine substrate detection; Leica Microsystems) for
10 min at room temperature. After being washed with dH20, the
sections were counterstained with Mayer Hematoxylin solution (New-
comer Supply, Middleton, WI), dehydrated through 100% EtOH,
cleared in xylene, mounted with synthetic resin mounting medium,
and coverslipped.
Slides were analyzed using bright field on a Nikon 80i microscope
(Nikon Instruments, Melville, NY) and images obtained using NIS-
Elements and Nikon Digital Sight Series color camera (DS-Fi1; Nikon
Instruments). All measurements were made using a 20 objective
lens. Digital RGB images were exported to Photoshop (Adobe,
Tucson, AZ). A neuron was considered labeled if the pSTAT3 ()
nucleus was clearly labeled. For each brain, all pSTAT3 () neurons
were counted bilaterally in adjacent sections at four levels of ARC
(bregma 3.48 to 2.76 mm). Values for each brain within a
treatment were averaged to obtain the mean of the treatment group.
Statistical Analyses
Values are presented as group means SE. Data were analyzed by
repeated-measures analysis of variance. Planned comparisons of treat-
ment means were evaluated by t-tests and paired t-tests. Differences
were considered significant if P 	 0.05.
RESULTS
Effects of Food Restriction-Induced Weight Loss in DIO
Rats on Food Intake, Body Weight, Body Fat, and
Plasma Leptin
A 40% reduction in daily intake of a 45% fat diet was
imposed for 2 or 4 wk in DIO rats, followed by 3 wk of free
access to the high-fat diet. After 2- and 4-wk food restriction,
body weight was reduced by 7 and 12% (Fig. 2A) and body fat
by 19 and 29%, respectively (Fig. 2B). Unrestricted DIO rats
were hyperleptinemic; after 2- and 4-wk restriction, plasma
leptin was reduced by 56 and 67%, respectively (Fig. 2C).
[Leptin levels in the unrestricted DIO rats are characterized
here as hyperleptinemic because in a separate experiment we
measured leptin levels of 22.9  2.4 ng/ml in unrestricted DIO
rats (699  17 g, 28  1% body fat; n  10) and 5.3  1.2
ng/ml in age-matched lean rats (517 16 g, 16 2% body fat;
n  10) (unpublished data).] Prolonged hyperphagia occurred
after 4 wk, but not 2 wk, of caloric restriction in the DIO rats
(Fig. 2D). After 3 wk of ad libitum refeeding, weight and body
fat regain were complete in both restricted groups (Fig. 2, A
and B), and plasma leptin rebounded completely after 2 wk, but
not 4 wk, of restriction (Fig. 2C). These results demonstrate
that food restriction-induced weight loss (and fat loss) in our
DIO rats reverses hyperleptinemia and induces a postrestriction
hyperphagia and weight (and fat) regain. This finding is con-
sistent with the hypothesis that weight loss in obese subjects
produces a relative leptin deficiency that activates orexigenic
and energy conservation mechanisms in the brain to restore
energy reserves.
Effects of Daily ip Infusions of Leptin and Exendin-4
Alone and Together on Post-Food Restriction-Induced
Hyperphagia, Weight Regain, and Plasma Leptin in
DIO Rats
Dose response effects of iv infusion of leptin on food intake
in lean rats. To define a leptin-dosing regimen for the weight-
reduced DIO rats, we first determined the dose response effects
of a 3-h iv infusion of leptin (2, 4, 6, and 12 nmol·kg1·h1) at
dark onset on food intake in lean rats. Leptin infusion dose-
dependently reduced food intake in lean rats (Figs. 3, A–D); the
minimal effective dose of 4 nmol·kg1·h1 significantly de-
creased 3- and 12-h cumulative intakes by 26 and 21%,
respectively. Leptin doses of 6 and 12 nmol·kg1·h1 reduced
food intake in a similar manner (Fig. 3, C and D).
Effects of daily iv infusions of leptin on food intake and body
weight in lean rats. We next determined the effects of twice
daily 3-h iv infusions of the minimal effective dose of leptin (4
nmol·kg1·h1) at the onset of the light and dark periods for 10
days on daily food intake, body weight, and body fat in lean
rats. Leptin produced a sustained 8–22% reduction in daily
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food intake for 10 days beginning on the 1st day of adminis-
tration (Fig. 3G) and reduced body weight and body fat by 6
and 53%, respectively, without lean mass being affected (data
not shown).
Effects of iv vs. ip infusion of leptin on food intake in lean
rats. We then compared the effects of a 3-h iv vs. ip infusion
of leptin at dark onset on food intake in lean rats, since the next
experiment determining the effects of leptin replacement for 3
wk on weight regain in weight-reduced DIO rats would ad-
minister leptin by ip infusion. At each dose, leptin reduced
food intake similarly whether administered by iv or ip infusion
(Fig. 3, E and F).
Effects of daily ip infusions of leptin and exendin-4 alone
and together on post-food restriction-induced hyperphagia,
weight regain, and plasma leptin in DIO rats. The 40% daily
food restriction for 4 wk produced a 10% weight loss in DIO
rats (Fig. 4A). During the subsequent 3-wk ad libitum feeding
period, the weight-reduced rats receiving daily vehicle infu-
sions (two 3-h ip infusions at the onset and end of the dark
period) were hyperphagic for 2 wk (Fig. 5A) and regained lost
weight (Fig. 4A). Hyperphagia occurred primarily through an
increase in meal size (Fig. 5B). Compared with these rats, weight-
reduced rats receiving leptin infusion (4 nmol·kg1·h1) during the
same two 3-h intervals were similarly hyperphagic, had similar
mean daily meal sizes and meal numbers, and regained weight
at the same rate (Figs. 4A and 5, A–C). In contrast, the two 3-h
infusions of exendin-4 (50 pmol·kg1·h1) prevented
postrestriction hyperphagia and weight regain by normalizing
meal size (Figs. 4A and 5, A and B). Prevention of weight gain
was identical in rats pair-fed the daily amount of food ingested
by the exendin-4-treated group (Fig. 4A), suggesting that ex-
endin-4 prevented weight regain by preventing hyperphagia.
Coadministration of leptin and exendin-4 did not reduce body
weight more than exendin-4 alone (Fig. 4A). Instead, leptin
began to attenuate the inhibitory effect of exendin-4 on food
intake, meal size, and weight regain by the end of the 2nd wk
of administration (Figs. 4A and 5, A and B). Our leptin dosing
regimen produced hyperleptinemia in the weight-reduced DIO
rats (Fig. 4B). Plasma leptin levels in animals receiving leptin
infusions were sevenfold greater than those in rats receiving
vehicle infusions and 17-fold greater than those in rats receiv-
ing exendin-4 infusions.
Leptin Sensitivity in Age-Matched Lean, DIO, and
Weight-Reduced DIO Rats
ARC pSTAT3 signaling 30 min after leptin injection (125
nmol/kg ip) was reduced significantly in DIO vs. lean rats
[70  15 vs. 370  107 pSTAT () cells, P 	 0.05] and in
DIO vs. weight-reduced DIO rats [70  15 vs. 300  33
pSTAT () cells, P 	 0.001]. In contrast, pSTAT3 signaling
was not different in weight-reduced DIO vs. age-matched lean
rats [300  33 vs. 370  107 pSTAT3 () cells, P  0.05].
Figure 6 shows representative ARC sections. pSTAT3 ()
cells were counted bilaterally from single sections at four
levels of ARC [bregma 3.48 to 2.76 mm (26)]. Together,
these results suggest that our DIO rats were hyperleptinemic
and leptin insensitive and that a food restriction-induced
weight loss of 10% in the DIO rats reversed hyperleptinemia
and normalized leptin sensitivity.
DISCUSSION
Administration of leptin to obese leptin-deficient rodents
(e.g., ob/ob mice) and the few humans who have this condition
Fig. 2. Body weight (A), body fat (B), plasma
leptin concentration (C), and daily food in-
take (D) in DIO rats in response to 40% daily
FR for 2 or 4 wk, followed by 3 wk of ad
libitum feeding. Values are means  SE.
Values labeled with different letters are dif-
ferent (P 	 0.05).
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reverses hypometabolism and hyperphagia and induces dra-
matic weight loss (47, 48). In contrast, most obese humans and
DIO rodents are hyperleptinemic and leptin insensitive (24).
Rosenbaum et al. (37) proposed that weight loss in obese
subjects produces a relative leptin deficiency that activates
orexigenic and energy conservation mechanisms in the brain to
restore energy reserves and that leptin replacement would
attenuate weight regain. In support of this hypothesis, they
showed that a 10% weight reduction in obese humans reduces
energy expenditure, satiation, and perception of the amount of
food eaten and that low-dose leptin replacement reverses these
effects (36, 37).
Here, we assessed whether hyperphagia and weight regain
following a food restriction-induced weight loss of 10% in DIO
Fig. 3. A–D: effects of 3-h intravenous (iv)
infusion of leptin on cumulative food intake
during 12-h dark period in 13–16 lean rats. In a
series of 4 experiments, normally fed rats re-
ceived a 3-h jugular vein infusion of vehicle or
leptin (2, 4, 6, or 12 nmol·kg1·h1) beginning
15 min before dark onset (time 0). E and
F: effects of 3-h iv or intraperitoneal (ip) infu-
sion of vehicle or leptin (4 or 6 nmol·kg1·h1)
at dark onset on cumulative food intake for 21 h
in 14–15 lean rats. Dark period was from 0 to
12 h. G: effects of two 3-h iv infusions of
vehicle or leptin (4 nmol·kg1·h1) at onset of
light and dark periods each day for 10 days on
daily food intake of normal chow diet in lean
rats. Values are means SE. *P	 0.05, †P	
0.01, and ‡P 	 0.001 compared with the vehi-
cle-treated group.
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rats is mediated by a reduction in leptin signaling to the brain.
Our results showed that weight loss in the DIO rats reversed
hyperleptinemia, increased leptin sensitivity, and induced a
postrestriction hyperphagia and weight (and fat) regain. How-
ever, daily systemic administration of leptin [two 3-h ip infusions at
the onset and end of the dark period (24 nmol·kg1·day1)] did not
attenuate hyperphagia and weight regain, nor did it affect mean
daily meal sizes or meal numbers in the weight-reduced DIO
rats. Together, these results do not support the hypothesis that
weight loss in obese subjects produces a relative leptin defi-
ciency that activates orexigenic and energy conservation mech-
anisms in the brain to restore energy reserves.
Numerous studies have shown that acute systemic adminis-
tration of long-acting GLP-1 receptor agonist exendin-4 can
rapidly and potently suppress food intake in lean and obese
subjects. Previously, we showed that in DIO rats two 3-h ip
infusions of exendin-4 at the onset and the end of the dark
period each day (0.15 nmol·kg1·day1) produced a sustained
20% reduction in daily food intake for 17 days and decreased
body weight by 7% (31). Here, we determined the effects of a
similar daily regimen of exendin-4 dosing alone and with leptin
(24 nmol·kg1·day1) for 3 wk on hyperphagia and weight
regain in weight-reduced DIO rats. Exendin-4 alone prevented
the post-restriction-induced increase in meal size, hyperphagia,
and weight regain. Thus, intermittent ip infusion of exendin-4
had a similar prolonged effect on food intake whether admin-
istered to weight-reduced or non-weight-reduced DIO rats.
Fig. 5. Effects of 3-h ip infusions of leptin (4 nmol·kg1·h1), exendin-4 (50
pmol·kg1·h1), and leptin  exendin-4 at onset and end of dark period each
day for 3 wk on mean daily food intake (A), mean daily meal size (B), and
mean daily number of meals (C) in DIO rats that had been 40% food restricted
daily for 4 wk. Values are means  SE. Values labeled with different letters
within each weekly period are different (P 	 0.05).
Fig. 4. Effects of 3-h ip infusions of leptin (4 nmol·kg1·h1), exendin-4 (50
pmol·kg1·h1), and leptin  exendin-4 at onset and end of dark period each
day for 3 wk on body weight (A) and plasma leptin concentration (B) in DIO
rats that had been 40% food restricted daily for 4 wk. Values are means  SE.
Values labeled with different letters are different (P 	 0.05).
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Prevention of weight gain in the weight-reduced rats in re-
sponse to exendin-4 administration was identical in rats pair-
fed the daily amount of food ingested by the exendin-4-treated
rats, which suggests that exendin-4 prevented weight regain by
preventing hyperphagia. However, coadministration of leptin
and exendin-4 did not reduce body weight more than exendin-4
alone. Rather, leptin began to attenuate the inhibitory effects of
exendin-4 on hyperphagia and weight regain by the end of the
2nd wk of administration.
The inability of leptin replacement to reduce food intake and
body weight in the weight-reduced DIO rats was not likely due
to leptin insensitivity at the start of leptin administration,
because age-matched lean and weight-reduced DIO rats exhib-
ited comparable leptin sensitivities that were significantly
greater than that observed in DIO rats. The inability of leptin
replacement to reduce food intake and body weight in the
weight-reduced DIO rats was also not likely due to leptin
dosing being too low to affect food intake, because similar
daily dosing produced a prolonged reduction in daily food
intake and body weight in lean rats consuming normal rat chow
(low fat). However, the weight-reduced DIO rats were pro-
vided a palatable high-fat diet instead of rat chow, and leptin
replacement has been reported to be less effective in reducing
intake of palatable food. Knight et al. (18) showed that a leptin
replacement dose that prevented hyperphagia and weight gain
in leptin-deficient ob/ob mice on a low-fat diet did not prevent
development of obesity in ob/ob mice on a high-fat diet despite
both groups of mice exhibiting normal leptin sensitivity. Fur-
thermore, wild-type mice developed the same degree of obesity
on the high-fat diet, yet they were hyperleptinemic and leptin
insensitive. These results suggest that sustained hyperleptine-
mia, rather than chronic ingestion of a high-fat diet, produces
leptin insensitivity and that leptin replacement alone may be
unable to prevent weight regain in weight-reduced obese sub-
jects exposed to palatable foods.
Another possible reason why leptin administration was un-
able to attenuate hyperphagia and weight regain in the weight-
reduced DIO rats is that our dosing regimen may have rapidly
produced leptin insensitivity. Our leptin-dosing regimen pro-
duced hyperleptinemia in the weight-reduced DIO rats, and
hyperleptinemia can produce leptin insensitivity (18). In our
study, plasma leptin levels in weight-reduced DIO rats receiv-
ing leptin infusions were sevenfold greater than those in
weight-reduced DIO rats receiving vehicle infusions and 17-
fold greater than those in weight-reduced DIO rats receiving
exendin-4 infusions. Our leptin-dosing regimen also appeared
to attenuate rather than enhance the inhibitory effect of exen-
din-4 on food intake and weight regain in the weight-reduced
DIO rats. This would be consistent with the idea that the high
leptin dose, by inducing leptin insensitivity, further reduced
leptin signaling to the brain, which further activated orexigenic
and energy conservation mechanisms to promote weight re-
gain. Thus, it remains to be determined whether a leptin-dosing
regimen that does not produce leptin insensitivity would atten-
uate hyperphagia and weight regain or enhance the efficacy of
exendin-4 to reduce food intake and body weight in weight-
reduced DIO rats.
No previous study has determined that chronic administra-
tion of leptin can attenuate weight regain or promote greater
weight loss in weight-reduced obese individuals. Neither con-
tinuous SQ infusion nor twice daily ip injection of leptin
prevented weight regain in weight-reduced DIO rats on a
high-fat diet (5, 6). However, only single leptin doses were
tested, and it is unclear whether they were ineffective because
they produced hyperleptinemia and leptin insensitivity or be-
cause increased leptin signaling alone is unable to suppress
eating of highly palatable foods (18, 24).
It remains to be determined whether chronic leptin admin-
istration can increase the efficacy of other anorexigenic sub-
stances to produce significant weight loss in obese subjects.
Continuous SQ administration of leptin with either sibutramine
(3) or amylin (40, 41) has been reported to synergistically
reduce food intake and body weight in DIO rats. However, rats
were likely not obese in these studies (i.e., relatively low
%body fat and/or plasma leptin), and very little if any actual
weight loss was produced by treatments: only 5% weight loss
in the study by Boozer et al. (3) and only prevention of weight
gain in the studies by Trevaskis and colleagues (40, 41). It is
also unclear whether the continuous SQ doses of leptin used in
these studies produced hyperleptinemia and leptin insensitiv-
ity.
In their recent review, Trevaskis et al. (42) reported that
coadministration of leptin and amylin is much less effective in
reducing body weight in heavier DIO-prone rats (550–800 g)
than in the lighter DIO-prone rats (450 g) that they typically
use and is not effective in humans with BMI 35. They
suggested that this is due to greater leptin insensitivity in the
more obese subjects. However, the apparent lower efficacy of
Fig. 6. Effects of ip injection of leptin (125
nmol/kg) on arcuate nucleus (ARC) phos-
phorylated signal transducer and activator of
transcription 3 signaling (denoted by arrows)
in age-matched lean rats (A), DIO rats (B),
and 10% weight-reduced DIO rats (C) (40
magnification).
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leptin and amylin to reduce body weight in heavier rats may be
an artifact of the way they define weight loss as percent
vehicle-corrected weight loss. A growing 450-g rat on a high-
fat diet would be expected to gain weight more rapidly as a
percentage of body weight than an older 800-g rat on the same
diet. Thus, for an amylin-leptin treatment to produce the same
percent vehicle-corrected weight loss in 450- and 800-g rats, a
treatment that only prevents weight gain in 450-g rats would
have to significantly reduce body weight in 800-g rats. Since
reducing body weight likely activates counteracting orexigenic
and energy conservation mechanisms much more so than does
prevention of weight gain, then the apparent lower efficacy of
amylin-leptin treatment in 800- vs. 450-g rats may be due to
greater activation of counteracting mechanisms in the heavier
rats rather than to greater leptin insensitivity. Thus, it remains
to be determined whether coadministration of leptin and amy-
lin or leptin with other anorexigenic substances can produce
significant weight loss in DIO rats if weight loss is defined as
percent change from initial body weight, as it is in human
clinical trials. Furthermore, since chronic hyperleptinemia can
cause leptin insensitivity, defining a leptin-dosing regimen that
produces maximal leptin signaling to the brain is critical for
determining whether leptin adjunct therapies can be effective.
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